Physician profile
Dele Ogunyemi
NPI 1548257199
$421.43
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $245 · 2021: $18.76.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $217.14 | 2019-2021 | |
| Allergan, INC. | $55.75 | 2020 | |
| Amgen INC. | $41.49 | 2019 | |
| Si-Bone, INC. | $25.17 | 2019 | |
| Assertio Therapeutics, INC. | $16.91 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.47 | 2019 | |
| Daiichi Sankyo INC. | $12.61 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.44 | 2019 | |
| Lilly USA, LLC | $12.34 | 2020 | |
| Biodelivery Sciences International, INC. | $12.11 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dele Ogunyemi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.